|Year : 2010 | Volume
| Issue : 2 | Page : 78-81
Effect of ascorbic acid supplementation on nitric oxide metabolites and systolic blood pressure in rats exposed to lead
Amani Mohammad1, Noroozzadeh Ali2, Badalzadeh Reza3, Khoshbaten Ali4
1 Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Physiology and Biophysic, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Young Researches Club of Tabriz Islamic Azad University, Tabriz, Iran
4 Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz; Research Center of Chemical Injuries (RCCI), Baqiyatallah University of Medical Sciences, Tehran, Iran
|Date of Submission||08-Sep-2008|
|Date of Decision||02-Nov-2008|
|Date of Acceptance||20-Apr-2010|
|Date of Web Publication||23-Jun-2010|
Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz
Source of Support: None, Conflict of Interest: None
Background: Extended exposure to low levels of lead causes high blood pressure in human and laboratory animals. The mechanism is not completely recognized, but it is relatively implicated with generation of free radicals, oxidant agents such as ROS, and decrease of available nitric oxide (NO). In this study, we have demonstrated the effect of ascorbic acid as an antioxidant on nitric oxide metabolites and systolic blood pressure in rats exposed to low levels of lead.
Materials and Methods: The adult male Wistar rats weighing 200-250 g were divided into four groups: control, lead acetate (receiving 100 ppm lead acetate in drinking water), lead acetate plus ascorbic acid (receiving 100 ppm lead acetate and 1 g/l ascorbic acid in drinking water), and ascorbic acid (receiving 1 g/l ascorbic acid in drinking water) groups. The animals were anesthetized with ketamin/xylazine (50 and 7 mg/kg, respectively, ip) and systolic blood pressure was then measured from the tail of the animals by a sphygmomanometer. Nitric oxide levels in serum were measured indirectly by evaluation of its stable metabolites (total nitrite and nitrate (NOc)).
Results: After 8 and 12 weeks, systolic blood pressure in the lead acetate group was significantly elevated compared to the control group. Ascorbic acid supplementation could prevent the systolic blood pressure rise in the lead acetate plus ascorbic acid group and there was no significant difference relative to the control group. The serum NOc levels in lead acetate group significantly decreased in relation to the control group, but this reduction was not significantly different between the lead acetate plus ascorbic acid group and the control group.
Conclusion: Results of this study suggest that ascorbic acid as an antioxidant prevents the lead induced hypertension. This effect may be mediated by inhibition of NOc oxidation and thereby increasing availability of NO.
Keywords: Blood pressure, lead, ascorbic acid, nitric oxide
|How to cite this article:|
Mohammad A, Ali N, Reza B, Ali K. Effect of ascorbic acid supplementation on nitric oxide metabolites and systolic blood pressure in rats exposed to lead. Indian J Pharmacol 2010;42:78-81
|How to cite this URL:|
Mohammad A, Ali N, Reza B, Ali K. Effect of ascorbic acid supplementation on nitric oxide metabolites and systolic blood pressure in rats exposed to lead. Indian J Pharmacol [serial online] 2010 [cited 2019 Dec 7];42:78-81. Available from: http://www.ijp-online.com/text.asp?2010/42/2/78/64501
| » Introduction|| |
Chronic exposure to low levels of lead causes high blood pressure in human and laboratory animals which persists after cessation of lead exposure. , The mechanism is not completely understood, but it seems to be related to generation of free radicals, oxidant agents such as ROS, and decrease of available nitric oxide (NO). Exposure to low levels of lead causes the production of free radicals such as superoxide anion, hydrogen peroxide, oxygen, and hydrogen radicals. ,, Oxidative stress plays an important role in lead-induced hypertension through inactivation of nitric oxide (NO) by ROS. Alleviation of oxidative stress using antioxidants could decrease blood pressure and increase available nitric oxide (NO) in lead-induced hypertension. , Ascorbic acid (vitamin C) a water soluble vitamin that is one of the important antioxidants in plasma and cell membranes that could act as a free radical (specially superoxide anion) scavenger and could increase the available nitric oxide through both protection from oxidation and increase in eNOS (endothelial nitric oxide synthase) activity. , Ascorbic acid also is associated with a reduction in vascular sensitivity to noradrenaline and enhancement of endothelium-dependent relaxation due to increased nitric oxide bioavailability. ,,
The aim of the present study was to investigate the effect of ascorbic acid supplementation as an antioxidant on blood pressure and nitric oxide metabolites level (total nitrite and nitrate (NOc) after acute (4-8 weeks) and subacute (12 weeks) exposure to low levels of lead acetate in rats.
| » Materials and Methods|| |
Adult male Wistar rats weighing 200-250 g were divided into four groups: control (CNTL), lead acetate (Ld) (receiving 100 ppm lead acetate in drinking water), lead acetate plus ascorbic acid (Ld+AA) (receiving 100 ppm lead acetate and 1g/l ascorbic acid in drinking water), and ascorbic acid (AA) (receiving 1 g/l ascorbic acid in drinking water) groups. The animals were anaesthetized with ketamin/xylazine (50 and 7 mg/kg, respectively, ip) and then systolic blood pressure were measured from the tail of the animals by a sphygmomanometer (PE300, Narco Biosystems) after stabilization of vital signs. Nitric oxide levels in serum were measured indirectly by evaluation of its stable metabolites nitrite and nitrate by the spectrophotometric method using the Griess reaction. A good correlation between endogenous NO production and nitrite/nitrate (NOc) levels in plasma, serum, and urine has been reported.  In the present study, nitrate was reduced to nitrite by vanadium chloride(III). Diazotization of sulfanilamide by nitrous acid and its conjugation with a bicyclic amine produced a chromophore which had maximum absorbance at 540 nm. , In addition, the weight of animals was measured in different weeks. Blood ascorbic acid concentration was measured in each group after 12 weeks using the spectrophotometric method. The serum ascorbic acid was reduced to dehydroascorbic acid by Cu 2+ and then conjugated with the aromatic dinitro-phenyl hydrazine to produce a chromophore which had maximum absorbance at 520 nm. 
Statistical comparison of data between the experimental groups with those obtained from the control group was performed by one-way ANOVA and then the Tukey-HSD test. The repeated measurement method used for comparison of data from the same groups but in different weeks. In all cases, a value of P<0.05 was considered statistically significant. Data are presented as means ± SEM.
| » Results|| |
There was no difference in animal weights among different experimental groups and the CNTL before the experiment and after 4, 8 and 12 weeks of receiving lead acetate and ascorbic acid [Figure 1].
The serum ascorbic acid concentration in the AA group (1.23 ± 0.01 mg/dl) and Ld+AA group (1.2 ± 0.01 mg/dl) was significantly higher than that in the CNTL group (0.8 ± 0.008 mg/dl) and Ld group (0.78 ± 0.007 mg/dl) after 12 weeks [Figure 2]. There was no significant difference in the serum ascorbic acid concentration between the AA group and Ld+AA group, as well as between the CNTL group and Ld group after 12 weeks [Figure 2].
After 4 weeks of lead treatment, systolic blood pressure in the Ld group was elevated (110.28 ± 4.88 mmHg) but was not significantly different in comparison with the CNTL group (101.28 ± 4.55 mmHg). Persistent usage of lead acetate increased the systolic blood pressure significantly to 127.14 ± 4.83 mmHg and 137.85 ± 4.14 mmHg level after 8 and 12 weeks, respectively, as compared to the value in the CNTL group [Figure 3]. No significant difference in the systolic blood pressure between the Ld+AA group and the CNTL group in 4 th , 8 th and 12th week was seen. There was no significant difference in the systolic blood pressure of the AA group and the CNTL group in 4 th , 8 th and 12th week [Figure 3].
After 4 weeks, the NOc level in the Ld group (46.05 ± 1.69 μM) significantly decreased relatively to the CNTL group (54.18 ± 1.63 μM) [Figure 4]. Prolonged administration of lead acetate ended into a more decrease in NOc level, there was a significant decrease in NOc level in the Ld group after 8 weeks (39.03 ± 2.10 μM vs 53.77 ± 1.59 μM) and after 12 weeks (32.12 ± 1.57 μM vs 52.06 ± 1.96 μM) as compared to their corresponding control value. NOc level in the Ld group after 8 weeks significantly decreased relatively to NOc level in the Ld group before the experiment. Also, there was significant decrease in NOc level in the Ld group after 12 weeks in comparison with the NOc level in the Ld group after 4 weeks [Figure 4]. There was no significant difference in NOc level between the Ld+AA group and the CNTL group, nor between the AA group and the CNTL group in 4 th , 8 th , and 12th week. On the other hand, there was a significant difference in NOc level between the Ld group and the Ld+AA group after 12 weeks [Figure 4].
| » Discussion|| |
The present study reveals that ascorbic acid can prevent the lead-induced hypertension via blocking NO oxidation by ROS and NO reduction. In the present study, administration of lead acetate and ascorbic acid in drinking water had no effect on food intake and water drinking. Karimi et al. reported similar results.  After 4 weeks, the systolic blood pressure increased, however non-significantly. Systolic blood pressure elevation was significant after 8 weeks of lead exposure and remained elevated after 12 weeks. These results are in agreement with another report by Ding et al.
Administration of ascorbic acid prevented the lead-induced hypertension; however, it seems that this prevention was not complete, nevertheless, there was no significant difference in the systolic blood pressure between the Ld+AA group and the CNTL group. There was a significant decrease in NOc level in the Ld group relative to the CNTL group in 4 th , 8 th , and 12 th week. Although the NOc level in the Ld+AA group had decreased in comparison with the CNTL group in 4 th , 8 th , and 12 th week, but it was not significant and it seems that the administration of ascorbic acid could prevent the decrease in NOc level and this prevention is not complete.
In recent studies, a good correlation has been reported between the blood lead levels and the hypertension.  High blood pressure has been reported in both acute and chronic exposure to lead.  In many studies, chronic exposure to low levels of lead caused a permanent increase in blood pressure.  Lead-induced hypertension have a close correlation with the increase in free radicals production and changes in nitric oxide metabolism. ,
It is also known that the changes in blood nitric oxide level is not solely the cause of lead-induced hypertension , and the other factors such as changes in ACE activity, in Ang II level, EDCF, endothelin, and in vascular responsiveness might be involved. ,
| » Conclusion|| |
The results of this study reveal that the decrease in available NO is the main mechanism of lead-induced hypertension, and ascorbic acid supplementation prevents the lead-induced hypertension via inhibition of NO oxidation and an increase in available NO.
| » References|| |
|1.||Sharp DS, Becker CE, Smith AH. Cronic low-level lead exposure: Its role in the pathogenesis of hypertension. Med Toxicol 1987;2:210-32. [PUBMED] |
|2.||Harlan WR. The relationship of blood lead levels to blood pressure in the US population. Environ Health Perspect 1988;78:9-13. [PUBMED] [FULLTEXT] |
|3.||Vaziri ND. Pathogenesis of lead-induced hypertension: Role of oxidative stress. J Hypertension 2002;20:15-20. |
|4.||NI Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 2004;66:2329-36. [PUBMED] [FULLTEXT] |
|5.||Ding Y, Gonick HC, Vaziri ND. Lead-induced hypertension: Increased hydroxyl radical production. Am J Hypertens 2001;14:169-73. [PUBMED] |
|6.||Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 1999;56:1492-8. [PUBMED] [FULLTEXT] |
|7.||Gurer H, Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning? Free Radic Biol Med 2000;29:927-45. [PUBMED] [FULLTEXT] |
|8.||Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, et al. Vitamin C as an antioxidant: Evaluation of its role in disease prevention. J Am Coll Nutr 2003;22:18-35. [PUBMED] [FULLTEXT] |
|9.||Huang A, Vita JA, Venema RC, Keaney JF. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular terahydrobiopterin. J Biol Chem 2000;275:17399-406. |
|10.||Newaz MA, Yousefipour Z, Nawal N. Modulation of nitric oxide synthase activity in brain, liver, and blood vessels of spontaneously hypertensive rats by ascorbic acid: Protection from free radical injury. Clin Exp Hypertens 2005;27:497-508. |
|11.||Uscio L, Milstien S, Richardson D, Smith L, Katusic Z. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003;92:88-95. |
|12.||Ettarh RR, Odigie IP, Adigun SP. Vitamin C lowers blood pressure and alters vascular responsiveness in salt-induced hypertension. Can J Physiol Pharmacol 2002;80:1199-202. |
|13.||Granger DL, Taintor RR, Boockvar KS, Hibbs JB. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 1996;268:142-51. |
|14.||Sun J, Zhang X, Broderick M, Fein H. Measurement of nitric oxide production in biological systems by using Griess reaction assay. Sensors 2003;3:276-84. |
|15.||Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5:62-71. [PUBMED] [FULLTEXT] |
|16.||Roe JH. Ascorbic acid. In: The Vitamins. Gyorgy P, Pearson WN, editors. New York: Acad Press; 1976. p. 27-51. |
|17.||Karimi GR, Khoshbaten A, Abdollahi M, Sharifzadeh M, Namiranian KH, Dehpour AR. Effects of subacute lead acetate administration on nitric oxide and cyclooxygenase pathways in rat isolated aortic ring. Pharmacol Res 2002;46:31-7. |
|18.||Ding Y, Vaziri ND, Gonick HC. Lead induced hypertension: Response to sequential infusions of L-arginine, superoxide dismutase and nitroprusside. Environ Res 1998;76:107-13. [PUBMED] [FULLTEXT] |
|19.||Sharp DS, Osterloh J, Becker CE, Bernard B, Smith AH, Fisher JM, et al. Blood pressure and blood lead concentration in bus drivers. Environ Health Perspect 1988;78:131-7. [PUBMED] [FULLTEXT] |
|20.||Nowack R, Wiecek A, Exner B, Gretz N, Ritz E. Chronic lead exposure in rats: Effects on blood pressure. Eur J Clin Invest 1993;23:433-43. |
|21.||Kasperczyk S, Birkner E, Kasperczyk A, Zalejska J. Activity of superoxide dismutase and catalase in people protractedly exposed to lead compounds. J Ann Agric Environ Med 2004;11:291-6. |
|22.||Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 1997;52:1042-6. [PUBMED] |
|23.||Heydari A, Norouzzadeh A, Khoshbaten A, Asgari A, Ghasemi A, Najafi S, et al. Effects of short-term and subchronic lead poisoning on nitric oxide metabolites and vascular responsiveness in rat. Toxicol lett 2006;166:88-94. [PUBMED] [FULLTEXT] |
|24.||Sharifi AM, Darabi R, Akbarloo N, Larijani B, Khoshbaten A. Investigation of circulatory and tissue ACE activity during development of lead-induced hypertension. Toxicol Lett 2004;153:233-8. [PUBMED] [FULLTEXT] |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
|This article has been cited by|
||How Biology Handles Nitrite
| ||Luisa B. Maia,José J. G. Moura |
| ||Chemical Reviews. 2014; 114(10): 5273 |
|[Pubmed] | [DOI]|
||Nitrite and Nitrite Reductases: From Molecular Mechanisms to Significance in Human Health and Disease
| ||Nicoletta Castiglione,Serena Rinaldo,Giorgio Giardina,Valentina Stelitano,Francesca Cutruzzolà |
| ||Antioxidants & Redox Signaling. 2012; 17(4): 684 |
|[Pubmed] | [DOI]|
||Nitrite and nitrite reductases: From molecular mechanisms to significance in human health and disease
| || Castiglione, N., Rinaldo, S., Giardina, G., Stelitano, V., Cutruzzolà, F. |
| ||Antioxidants and Redox Signaling. 2012; 17(4): 684-716 |